2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In Partnership With:
Conference | SGO Annual Meeting
Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.
“What we showed is that, in the first 13 patients [with stage I disease] accrued to the study, there were 2 confirmed and an additional 2 unconfirmed partial responses exceeding the predefined threshold.”
Rachel N. Grisham, MD, an associate attending physician at Memorial Sloan Kettering Cancer Center; section head of Ovarian Cancer; and director of Gynecologic Medical Oncology, at Memorial Sloan Kettering Cancer Center Westchester, discusses interim results from a phase 2 study (NCT05787561), which evaluated avutometinib (VS-6766) plus defactinib (VS-6063) in patients with advanced or recurrent gynecologic mesonephric cancer.